Author details

Full Name

Gao Zhang

Affiliation

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36634707	Targeting TBK1 to overcome resistance to cancer immunotherapy.	Nature	2023
35247901	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.	Clin Cancer Res	2022
35685885	Carnosol Maintains Intestinal Barrier Function and Mucosal Immune Homeostasis in DSS-Induced Colitis.	Frontiers in Nutrition	2022
36139353	Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance.	Cells	2022
36452156	Establishment of lung adenocarcinoma classification and risk model based on necroptosis-related genes.	Frontiers in Genetics	2022
34937742	Costimulation of Î³Î´TCR and TLR7/8 promotes VÎ´2 T-cell antitumor activity by modulating mTOR pathway and APC function.	J Immunother Cancer	2021
33941922	Evolution of delayed resistance to immunotherapy in a melanoma responder.	Nat Med	2021
33441554	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.	Nat Commun	2021
34304249	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.	Oncogene	2021
34462276	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.	Cancer Res	2021
34654806	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.	Nat Commun	2021
34593527	A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.	Clin Cancer Res	2021
32953781	EFCC1 as a putative prognostic biomarker in lung adenocarcinoma.	Annals of Translational Medicine (discontinued)	2020
33371144	A DNA methylation-associated nomogram predicts the overall survival of osteosarcoma.	Medicine (United States)	2020
32820016	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.	Clin Cancer Res	2020
32571981	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.	Mol Cancer Res	2020
32908002	Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.	Sci Transl Med	2020
31375515	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors.	Clin Cancer Res	2019
31729408	Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.	Sci Rep	2019
30442709	PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.	Cancer Discov	2019
30532003	Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.	Nature	2019
30765391	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.	Clin Cancer Res	2019
31519915	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.	Nat Commun	2019
30858377	Author Correction: Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.	Nat Commun	2019
30858180	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.	Mol Syst Biol	2019
31433975	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming.	Cell Rep	2019
29101162	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.	Cancer Discov	2018
30072397	A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.	Cancer Research	2018
30209241	Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival.	EMBO J	2018
30388455	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.	Cell	2018
29959144	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.	Clin Cancer Res	2018
30533193	Inducing rapid telomere irreparable damage in telomerase-expressing cancers.	Oncotarget	2018
30575721	Loss of Phd2 cooperates with BRAF<sup>V600E</sup> to drive melanomagenesis.	Nat Commun	2018
30333558	Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.	Nat Med	2018
30089911	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.	Nature	2018
30132561	Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siâ¿¿SAÎ¤B1 in ovarian cancer.	Oncology Reports	2018
30038220	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.	Nat Med	2018
30127394	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.	Nat Med	2018
29563139	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.	Clin Cancer Res	2018
29650805	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.	EMBO Mol Med	2018
29492189	Distinct histone modifications denote early stress-induced drug tolerance in cancer.	Oncotarget	2017
28953887	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.	Nature	2017
28899863	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.	Cancer Discov	2017
28898698	Enhancing CD8<sup>+</sup> T Cell Fatty Acid Catabolism withinÂ a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.	Cancer Cell	2017
28445987	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.	Oncotarget	2017
28484090	Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.	Oncotarget	2017
28928360	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.	Nat Commun	2017
28473531	Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer.	Cancer Res	2017
29141225	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.	Cell Rep	2017
27977682	PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.	PLoS Genet	2016